On Friday, Shares of BlackBerry Limited (NASDAQ:BBRY), lost -2.41% to $7.28.
BlackBerry Limited agreed to buy Good Technology Corp. for $425 million, gaining new mobile device-administration customers while removing one of its competitors in that business, according to Bloomberg.
Good Technology, based in Sunnyvale, California, builds applications to assist employees work securely from their personal phones. It counts all of the G7 governments and the world’s 10 largest banks and law firms among its 6,200 customers, BlackBerry said in a statement Friday. Bloomberg Reports
The acquisition removes a rival that had taken some of BlackBerry’s clients as more workers switched from employer-offered BlackBerrys to their own iPhones and Android devices. Bloomberg added.
BlackBerry Limited provides wireless communications solutions worldwide. The company offers BlackBerry wireless solutions, which comprise the sale of BlackBerry handheld devices; and the provision of data communication, and compression and security infrastructure services enabling BlackBerry handheld wireless devices to send and receive wireless messages and data. It also provides BlackBerry 10 smartphones; BlackBerry Enterprise Service (BES) 10 and BES 12, which are enterprise mobility administration solutions; QNX software for embedded markets; cloud-based BlackBerry Internet of Things platform; and BBM, an instant mobile to mobile private messaging service.
Shares of Abbott Laboratories (NYSE:ABT), declined -2.42% to $43.07, during its last trading session.
Abbott Laboratories declared positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott’s fully dissolving Absorb™ heart stent to XIENCE ®, Abbott’s market-leading, permanent drug eluting stent. The trial was conducted in 38 sites in Japan and enrolled 400 people with coronary artery disease, the most common form of heart disease. The results will be featured at a late-breaking session recently at ESC Congress 2015, an annual event of the European Society of Cardiology that brings together cardiologists from around the world, with the aim of reducing the burden of cardiovascular disease. In addition, the data was published simultaneously in the European Heart Journal.
Absorb is a first-of-its-kind device that functions like a permanent, metallic stent by opening a blocked artery in the heart, restoring blood flow and providing relief from symptoms of CAD. However, unlike a metallic stent, which permanently restricts vessel movement and limits future treatment options, Absorb is made of a naturally dissolvable material that leaves behind a restored vessel free of a permanent implant, with the potential to flex, pulse and dilate in response to various demands on the heart, based on people’s lifestyle and activities.
Last year, Abbott declared positive one-year clinical results from ABSORB II, the world’s first prospective, randomized, controlled trial comparing the safety and effectiveness of Absorb to XIENCE. At one year, overall clinical outcomes for Absorb were comparable to XIENCE. The trial, conducted primarily in Europe, comprised 501 people with CAD.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
Finally, Johnson Controls Inc. (NYSE:JCI), ended its last trade with -0.75% loss, and closed at $39.68.
CBRE Group, Inc. (CBG) declared that it has closed the acquisition of Johnson Controls, Inc.’s (JCI) Global Workplace Solutions business. Global Workplace Solutions is a market-leading provider of enterprise facilities administration solutions for global corporations and other large occupiers of commercial real estate. Global Workplace Solutions had revenue of more than $3.0 billion in calendar year 2014.
“This is a very exciting step for CBRE,” said Bob Sulentic, the company’s president and chief executive officer. “It advances our strategy of delivering the highest quality, globally integrated services to major occupiers and builds our relationships with many of the world’s most prominent corporations. We are assisting our clients to enhance their competitive position by aligning every aspect of how they lease, own, use and operate real estate.”
The advantages of outsourcing real estate services, coupled with the high quality of CBRE’s offering, have fueled long-term, double-digit revenue growth for its occupier outsourcing business line. The addition of Global Workplace Solutions’ expertise around the world in technical engineering, supply chain administration, critical facilities and other capabilities adds significantly to CBRE’s already-robust service offering for occupiers.
Global Workplace Solutions is the largest provider of facilities administration services outside the U.S., while CBRE’s facilities administration services are weighted to the Americas. The combined service offering will provide clients with materially greater scale advantages in virtually every corner of the world.
Johnson Controls, Inc. operates as a diversified technology and industrial company worldwide. Its Building Efficiency segment designs, produces, markets, and installs integrated heating, ventilating, and air conditioning systems, in addition to building administration systems, controls, and security and mechanical equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
